S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   165.06 (-1.19%)
MSFT   399.78 (-1.11%)
META   484.49 (-3.45%)
GOOGL   154.04 (-1.26%)
AMZN   174.75 (-2.49%)
TSLA   149.39 (-0.36%)
NVDA   810.69 (-4.25%)
AMD   149.25 (-3.76%)
NIO   3.83 (-4.25%)
BABA   68.81 (-0.10%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   107.74 (-3.74%)
GE   149.22 (-2.43%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.23 (+10.62%)
PFE   25.78 (+1.54%)
PYPL   62.19 (+0.14%)
XOM   120.10 (+1.33%)
S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   165.06 (-1.19%)
MSFT   399.78 (-1.11%)
META   484.49 (-3.45%)
GOOGL   154.04 (-1.26%)
AMZN   174.75 (-2.49%)
TSLA   149.39 (-0.36%)
NVDA   810.69 (-4.25%)
AMD   149.25 (-3.76%)
NIO   3.83 (-4.25%)
BABA   68.81 (-0.10%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   107.74 (-3.74%)
GE   149.22 (-2.43%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.23 (+10.62%)
PFE   25.78 (+1.54%)
PYPL   62.19 (+0.14%)
XOM   120.10 (+1.33%)
S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   165.06 (-1.19%)
MSFT   399.78 (-1.11%)
META   484.49 (-3.45%)
GOOGL   154.04 (-1.26%)
AMZN   174.75 (-2.49%)
TSLA   149.39 (-0.36%)
NVDA   810.69 (-4.25%)
AMD   149.25 (-3.76%)
NIO   3.83 (-4.25%)
BABA   68.81 (-0.10%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   107.74 (-3.74%)
GE   149.22 (-2.43%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.23 (+10.62%)
PFE   25.78 (+1.54%)
PYPL   62.19 (+0.14%)
XOM   120.10 (+1.33%)
S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   165.06 (-1.19%)
MSFT   399.78 (-1.11%)
META   484.49 (-3.45%)
GOOGL   154.04 (-1.26%)
AMZN   174.75 (-2.49%)
TSLA   149.39 (-0.36%)
NVDA   810.69 (-4.25%)
AMD   149.25 (-3.76%)
NIO   3.83 (-4.25%)
BABA   68.81 (-0.10%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   107.74 (-3.74%)
GE   149.22 (-2.43%)
CGC   8.13 (+3.83%)
DIS   112.07 (-0.32%)
AMC   3.23 (+10.62%)
PFE   25.78 (+1.54%)
PYPL   62.19 (+0.14%)
XOM   120.10 (+1.33%)
Free Trial
NYSEAMERICAN:PFNX

Pfenex (PFNX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free PFNX Stock Alerts
$12.75
0.00 (0.00%)
(As of 10/1/2020)
Compare
Today's Range
$12.75
▼
$12.75
50-Day Range
N/A
52-Week Range
$5.26
▼
$14.00
Volume
N/A
Average Volume
503,865 shs
Market Capitalization
$437.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
PFNX stock logo

About Pfenex Stock (NYSEAMERICAN:PFNX)

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

PFNX Stock Price History

PFNX Stock News Headlines

January 31, 2024 | morningstar.com
NKY Medical Holdings Ltd Class A 300109
September 25, 2022 | seekingalpha.com
Ligand Pharmaceuticals: Struggling Along (NASDAQ:LGND) - Seeking Alpha
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
August 15, 2022 | businesswire.com
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update - Business Wire
August 9, 2022 | businesswire.com
Ligand Reports Second Quarter 2022 Financial Results - Business Wire
August 8, 2022 | stockhouse.com
2022-08-08 | NDAQ:LGND | Press Release | Ligand Pharmaceuticals Incorporated - Stockhouse
May 17, 2022 | finance.yahoo.com
Osteoporosis Therapeutics Market to Top US$ 14 Bn Valuation by 2026: Fact.MR Analysis - Yahoo Finance
May 5, 2022 | streetinsider.com
Ligand Reports First Quarter 2022 Financial Results - StreetInsider.com
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
May 4, 2022 | marketscreener.com
Ligand Reports First Quarter 2022 Financial Results - Marketscreener.com
March 29, 2022 | seekingalpha.com
Ligand Pharmaceuticals: Moving Parts Keep Moving - Seeking Alpha
March 24, 2022 | prnewswire.com
Global Pharma, Biotech and Diagnostics Joint Venture Partnering Deal Terms and Agreements Analysis Report 2021 with Example Case Studies of Agila Specialties/Pfenex and Dance Biopharm/Harmony Asset - PR Newswire
February 17, 2022 | businesswire.com
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results - Business Wire
February 15, 2022 | businesswire.com
Pipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors - Business Wire
January 14, 2022 | marketscreener.com
LIGAND PHARMACEUTICALS INC : Termination of a Material Definitive Agreement (form 8-K) - marketscreener.com
January 5, 2022 | businesswire.com
Dr. Hubert Chen Joins ADARx Pharmaceuticals as Chief Medical Officer - Business Wire
November 10, 2021 | nasdaq.com
Solid Nutrition Unit to Aid Archer Daniels (ADM) Amid Cost Woes - Nasdaq
November 10, 2021 | nasdaq.com
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - Nasdaq
November 10, 2021 | nasdaq.com
fuboTV Falls 7% Despite Solid Q3 Results - Nasdaq
November 9, 2021 | marketscreener.com
LIGAND PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com
November 9, 2021 | businesswire.com
Ligand Reports Third Quarter 2021 Financial Results - Business Wire
September 23, 2021 | benzinga.com
Global Joint Venture Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021 - B - Benzinga
September 7, 2021 | yahoo.com
Ophthalmology Biosimilars Market Report 2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast - Yahoo Finance
July 30, 2021 | fool.com
Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript - Motley Fool
July 29, 2021 | businesswire.com
Ligand Reports Second Quarter 2021 Financial Results - Business Wire
See More Headlines
Receive PFNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfenex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/07/2020
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:PFNX
Previous Symbol
NYSEMKT:PFNX
CUSIP
N/A
CIK
N/A
Web
www.pfenex.com
Phone
+1-858-3524400
Fax
N/A
Employees
71
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
34,297,000
Free Float
N/A
Market Cap
$437.29 million
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Evert B. Schimmelpennink (Age 47)
    CEO, Pres, Sec. & Director
  • Ms. Patricia Lady C.M.A. (Age 61)
    CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer
  • Mr. Patrick K. Lucy (Age 51)
    Chief Bus. Officer
  • Dr. Hubert C. Chen (Age 50)
    Advisor
  • Ms. Susan A. Knudson (Age 55)
    Chief Financial Officer

Key Competitors

View All Competitors

PFNX Stock Analysis - Frequently Asked Questions

How were Pfenex's earnings last quarter?

Pfenex Inc. (NYSEAMERICAN:PFNX) posted its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.07. The biotechnology company had revenue of $0.68 million for the quarter, compared to analysts' expectations of $3.75 million.
Read the conference call transcript.

What other stocks do shareholders of Pfenex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfenex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Verastem (VSTM), SCYNEXIS (SCYX), TG Therapeutics (TGTX), TherapeuticsMD (TXMD), Gilead Sciences (GILD), Novavax (NVAX) and Ocular Therapeutix (OCUL).

How do I buy shares of Pfenex?

Shares of PFNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:PFNX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith